Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

517 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Medication overuse and drug addiction: a narrative review from addiction perspective.
Takahashi TT, Ornello R, Quatrosi G, Torrente A, Albanese M, Vigneri S, Guglielmetti M, Maria De Marco C, Dutordoir C, Colangeli E, Fuccaro M, Di Lenola D, Spuntarelli V, Pilati L, Di Marco S, Van Dycke A, Abdullahi RA, Maassen van den Brink A, Martelletti P; European Headache Federation School of Advanced Studies (EHF-SAS). Takahashi TT, et al. Among authors: albanese m. J Headache Pain. 2021 Apr 28;22(1):32. doi: 10.1186/s10194-021-01224-8. J Headache Pain. 2021. PMID: 33910499 Free PMC article. Review.
Persistent post-traumatic headache: a migrainous loop or not? The clinical evidence.
Labastida-Ramírez A, Benemei S, Albanese M, D'Amico A, Grillo G, Grosu O, Ertem DH, Mecklenburg J, Fedorova EP, Řehulka P, di Cola FS, Lopez JT, Vashchenko N, MaassenVanDenBrink A, Martelletti P; European Headache Federation School of Advanced Studies (EHF-SAS). Labastida-Ramírez A, et al. Among authors: albanese m. J Headache Pain. 2020 May 24;21(1):55. doi: 10.1186/s10194-020-01122-5. J Headache Pain. 2020. PMID: 32448142 Free PMC article. Review.
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study).
Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Pierangeli G, Lovati C, Aguggia M, d'Onofrio F, Doretti A, Di Fiore P, Finocchi C, Rao R, Bono F, Ranieri A, Albanese M, Cevoli S, Barbanti P; GARLIT Study Group. Vernieri F, et al. Among authors: albanese m. J Headache Pain. 2021 May 3;22(1):35. doi: 10.1186/s10194-021-01247-1. J Headache Pain. 2021. PMID: 33941080 Free PMC article.
Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance.
Sacco S, Lampl C, Maassen van den Brink A, Caponnetto V, Braschinsky M, Ducros A, Little P, Pozo-Rosich P, Reuter U, Ruiz de la Torre E, Sanchez Del Rio M, Sinclair AJ, Martelletti P, Katsarava Z; Burden and Attitude to Resistant and Refractory (BARR) Study Group. Sacco S, et al. J Headache Pain. 2021 May 18;22(1):39. doi: 10.1186/s10194-021-01252-4. J Headache Pain. 2021. PMID: 34006218 Free PMC article.
Correction to: Medication overuse and drug addiction: a narrative review from addiction perspective.
Takahashi TT, Ornello R, Quatrosi G, Torrente A, Albanese M, Vigneri S, Guglielmetti M, De Marco CM, Dutordoir C, Colangeli E, Fuccaro M, Di Lenola D, Spuntarelli V, Pilati L, Di Marco S, Van Dycke A, Abdullahi RA, van den Brink AM, Martelletti P; European Headache Federation School of Advanced Studies (EHF-SAS). Takahashi TT, et al. Among authors: albanese m. J Headache Pain. 2021 Jul 5;22(1):64. doi: 10.1186/s10194-021-01275-x. J Headache Pain. 2021. PMID: 34225669 Free PMC article. No abstract available.
Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study).
Barbanti P, Egeo G, Aurilia C, d'Onofrio F, Albanese M, Cetta I, Di Fiore P, Zucco M, Filippi M, Bono F, Altamura C, Proietti S, Bonassi S, Vernieri F; FRIEND-Study Group. Barbanti P, et al. Among authors: albanese m. J Headache Pain. 2022 Apr 9;23(1):46. doi: 10.1186/s10194-022-01396-x. J Headache Pain. 2022. PMID: 35397503 Free PMC article.
Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
Barbanti P, Aurilia C, Cevoli S, Egeo G, Fofi L, Messina R, Salerno A, Torelli P, Albanese M, Carnevale A, Bono F, D'Amico D, Filippi M, Altamura C, Vernieri F; EARLY Study Group. Barbanti P, et al. Among authors: albanese m. Headache. 2021 Oct;61(9):1351-1363. doi: 10.1111/head.14194. Epub 2021 Jul 26. Headache. 2021. PMID: 34309862
Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study).
Barbanti P, Egeo G, Aurilia C, d'Onofrio F, Albanese M, Cetta I, Di Fiore P, Zucco M, Filippi M, Bono F, Altamura C, Proietti S, Bonassi S, Vernieri F; and for the FRIEND-Study Group. Barbanti P, et al. Among authors: albanese m. J Headache Pain. 2022 Apr 28;23(1):51. doi: 10.1186/s10194-022-01422-y. J Headache Pain. 2022. PMID: 35484489 Free PMC article. No abstract available.
Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study).
Barbanti P, Egeo G, Aurilia C, d'Onofrio F, Albanese M, Cetta I, Di Fiore P, Zucco M, Filippi M, Bono F, Altamura C, Proietti S, Bonassi S, Vernieri F; FRIEND-Study Group. Barbanti P, et al. Among authors: albanese m. J Headache Pain. 2022 Jun 7;23(1):64. doi: 10.1186/s10194-022-01434-8. J Headache Pain. 2022. PMID: 35672670 Free PMC article. No abstract available.
The first report of the Italian Migraine Registry (I-GRAINE).
Barbanti P, Egeo G, Aurilia C, Fiorentini G, Proietti S, Tomino C, Bonassi S; Italian Migraine Registry Study Group. Barbanti P, et al. Neurol Sci. 2022 Sep;43(9):5725-5728. doi: 10.1007/s10072-022-06214-5. Epub 2022 Jul 8. Neurol Sci. 2022. PMID: 35802219
517 results